A randomized phase III trial of postoperative adjuvant oral fluoropyrimidine vs. sequential paclitaxel / oral fluoropyrimidine; and UFT vs. S1 for T3 / T4 gastric carcinoma: the Stomach Cancer Adjuvant Multi-institutional Trial Group (SAMIT) Trial.

Trial Profile

A randomized phase III trial of postoperative adjuvant oral fluoropyrimidine vs. sequential paclitaxel / oral fluoropyrimidine; and UFT vs. S1 for T3 / T4 gastric carcinoma: the Stomach Cancer Adjuvant Multi-institutional Trial Group (SAMIT) Trial.

Completed
Phase of Trial: Phase III

Latest Information Update: 12 May 2016

At a glance

  • Drugs Gimeracil/oteracil/tegafur (Primary) ; Paclitaxel (Primary) ; Tegafur/uracil (Primary)
  • Indications Gastric cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms SAMIT
  • Most Recent Events

    • 04 Jun 2013 Primary endpoint 'Disease-free-survival' has not been met.
    • 04 Jun 2013 Status changed from active, no longer recruiting to completed.
    • 04 Jun 2013 Results presented at the 49th Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top